WSJ: Siga's billionaire owner could derail $2.8B drug contract
After SIGA announced that it has been tapped as the likely winner of a $2.8 billion federal contract, the SBA is now threatening to blow up the deal.
Just weeks after Siga Technologies ($SIGA) announced that it has been tapped as the likely winner of a $2.8 billion federal contract for a new smallpox drug, the SBA is now threatening to blow up the deal after citing the developer's close ties to billionaire Ron Perelman. The Wall Street Journal says the agency sent a letter to Siga that it is "controlled by and affiliated with" MacAndrews & Forbes--which is owned by Perelman. And the news sparked a rout on Siga's stock price, with shares plunging 23 percent.
Siga had been singled out by a newly reenergized BARDA to deliver 1.7 million courses of an antiviral for smallpox for the country's strategic stockpile. But the hefty contract is intended to go to a small company, and Siga's lead position in the race to win it quickly earned a challenge from one of its competitors.
"We notified Barda in July 2009 that Siga did not qualify for a small-business set-aside," Chimerix Chief Executive Kenneth Moch tells the WSJ
Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News 3 ways ChatGPT will impact pharma marketing teams
What does the rise of AI-powered chatbots such as ChatGPT and GPT-4 mean for pharma marketeers? -
News Eli Lilly, Novo Nordisk, and Sanofi cut insulin prices by up to 78%
Insulin prices have dropped in a stark play by the three biggest makers of the product, after calls from the top of the US government. -
News Open letter challenges EU Commission on medicine supply chain
In an open letter to the European Commission, Medicines for Europe calls for a new medicine security contract with their goal to improve access to medicine and ensure a secure supply chain to Europe.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance